Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer.

Ozaki, Yukinori; Tsurutani, Junji; Mukohara, Toru; Iwasa, Tsutomu; Takahashi, Masato; Tanabe, Yuko; Kawabata, Hidetaka; Masuda, Norikazu; Futamura, Manabu; Minami, Hironobu; Matsumoto, Koji; Yoshimura, Kenichi; Kitano, Shigehisa; Takano, Toshimi.

Afiliação

Ozaki Y; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Tsurutani J; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Mukohara T; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
Iwasa T; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takahashi M; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan.
Tanabe Y; Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan.
Kawabata H; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Masuda N; Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan.
Futamura M; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Minami H; Department of Breast and Endocrine Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Matsumoto K; Breast Surgery, Gifu University Hospital, Gifu, Japan.
Yoshimura K; Medical Oncology/Hematology, Internal Medicine, School of Medicine, Kobe University, Hyogo, Japan.
Kitano S; Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan.
Takano T; Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima University, Hiroshima, Japan.